APA

Walter R. B., Boyle K. M., Appelbaum F. R., Bernstein I. D. & Pagel J. M. (20080716). Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. : Blood.

Chicago

Walter Roland B, Boyle Kelli M, Appelbaum Frederick R, Bernstein Irwin D and Pagel John M. 20080716. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. : Blood.

Harvard

Walter R. B., Boyle K. M., Appelbaum F. R., Bernstein I. D. and Pagel J. M. (20080716). Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. : Blood.

MLA

Walter Roland B, Boyle Kelli M, Appelbaum Frederick R, Bernstein Irwin D and Pagel John M. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. : Blood. 20080716.